$heff's $tation of $tocks & $olid DD

[Investor100]

BPAX:BioSante’s Pancreas Cancer Vaccine Shows over 60% Survival Increase in Newly Presented Study

One year survival increased from 7% to 27%

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX - News) today announced presentation of results from a Phase Ib clinical study that show its GVAX Pancreas cancer vaccine increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma (PDA), from 3.3 months when treated with ipilimumab (IPI; Yervoy; BMS), to 5.5 months on the combination of IPI plus GVAX Pancreas, an increase of more than 60 percent. The study was not powered for a direct comparison. In addition, the IPI/GVAX Pancreas combination demonstrated an increase in one year survival, from 7 percent to 27 percent. A new multicenter clinical study is planned to begin this year.

http://finance.yahoo.com/news/BioSante-Pancreas-Cancer-bw-1312072336.html?x=0

Investor 100